MedTrace Logo

Experiences With HDR-brachytherapy in Norway

NCT03162523 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 325

Last updated 2017-05-25

No results posted yet for this study

Summary

There are 3 articles that will be written about the experience with HDR-brachytherapy (HDR-BT) in patients with high-risk prostate cancer in Norway as part of a doctorial thesis-project. The project will focus on survival, side-effects and dosimetry variables as the main points of interest.

Conditions

Interventions

RADIATION

High-Dose Rate Brachytherapy

Sponsors & Collaborators

  • University of Oslo

    collaborator OTHER

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Trude Wedde, MD · Oslo University Hospital

Eligibility

Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2016-10-15
Completion
2016-10-15

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03162523 on ClinicalTrials.gov